Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.59 |
| ▸ | NQO2 | P16083 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680163 | 0.85 | KDM4E (0.53) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL16680098 | 0.85 | KDM4E (0.53) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL10956862 | 0.81 | ALDH1A1 (0.44) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL10954823 | 0.79 | CYP19A1 (0.58) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL7028988 | 0.76 | NQO2 (0.59) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL16166967 | 0.75 | KDM4E (0.51) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL31685031 | 0.75 | KDM4E (0.51) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL1381227 | 0.75 | KDM4E (0.51) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| SCHEMBL27296016 | 0.75 | KDM4E (0.51) | CYP19A1NQO2KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7516809 | 0.73 | KDM4E (0.50) | CYP19A1NQO2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| EP-0393574-B1 | Hexitol derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5053408-A | Cardiovascular disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | CNR2, CNR1, GRIN2C | CYP19A1 1294/4885NQO2 85/4885KDM4E 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.